Home ›
Acute Myeloid (AML) Leukemia Trials ›
NCT06810791
HVA vs IA/DA or VA in the Treatment of ND HR-AML
The aim of this study is to evaluate the safety and efficacy of homohartonine combined with venetoclax and azacitidine (HVA) versus intensive chemotherapy (IA/DA) or venetoclax combined with azacitidine (VA) in newly diagnosed high-risk AML patients.
Trial Details
NCT ID NCT06810791
Phase PHASE3
Sponsor Nanfang Hospital, Southern Medical University
Status RECRUITING
Cancer Type Acute Myeloid (AML) Leukemia
Interventions HVA VA Standard Chemotherapy
Locations (sample) Guangzhou, Guangdong, China|23.11667,113.25
Key Eligibility Criteria
According to the world health organization (WHO) classification of newly diagnosed with AML patients; Age ≥18 years old; High-risk patients should meet any of the following criteria: ① High risk group according to the European Leukemia Risk stratification (ELN) 2022; … Patients did not receive anti-AML therapy (except leukopenia therapy, such as hydroxyurea or cytarabine \< 1.0g/d) after the diagnosis of AML;
For full eligibility, visit ClinicalTrials.gov .